PeptideLabs Logo
PeptideLabs
All profiles

Tesamorelin

Peptide · Endocrine signals

Stimulates endogenous growth-hormone release; approval is limited to a narrowly defined indication.

Approved for specific usesWADA
LibraryNo account · this device only

Also known as: TH-9507 · GHRH analogue · TSM

Use at a glance

Tesamorelin

Stimulates endogenous growth-hormone release; approval is limited to a narrowly defined indication.

Medicine instructions · named product only

Product or source: Tesamorelin · EGRIFTA WR · 11.6 mg

What amount?
1.28 mg = 0.16 ml
How often?
once per day
What time of day?
Time of day not stated here
What period?
Not stated here
How is it used?
An approved powder medicine has its own instructions for preparation and administration.
Does it need mixing?
Yes, if the product instructions require it. Use its specified liquid and volume; another brand may differ.
View preparationCheck sources
More factsPeptide · Endocrine signals
Classification
Peptide · Endocrine signals
Research focus
Stimulates endogenous growth-hormone release; approval is limited to a narrowly defined indication.
Evidence
Established
Status
Approved for specific uses

Approved uses exist, but dose, formulation, device and monitoring are product- and indication-specific. A community table cannot replace the prescribing information or a prescription.

Schedule explained in detailApproved medicine

Amount status

EGRIFTA WR label: 1.28 mg =0.16 ml once daily subcutaneously into the abdomen, exclusively for the approved HIV lipodystrophy indication. Not for weight loss.

Profile evidence level: established.

Timing

Once daily; WR, SV and research vials are not interchangeable.

No individual recommendation.

Cycle/duration

Clinician-managed treatment with benefit/IGF-1/glucose monitoring; no freely designed community cycle.

No individual recommendation.

External community reference availableThe external page is used only to document community claims. Advertising and affiliate material were excluded; its content is neither approval nor proof of quality.

External community reference available

The external page is used only to document community claims. Advertising and affiliate material were excluded; its content is neither approval nor proof of quality.

Open community source

Mixing & calculations

Yes, if the product instructions require it. Use its specified liquid and volume; another brand may differ.

See calculation examplesFollow sample figures to understand mg, ml and scale markings.

Documented vial and fluid examples

The table shows only the arithmetic for explicitly stated inputs. It confirms neither vial content nor stability, sterility or an appropriate target amount.

11.6 mg · diluent specified by the label: 1.3 ml

Product-specific prescribing information
Calculated amount1.28 mg
Concentration8,000 µg/ml
U-10016 U
Volume0.16 ml
All preparation informationProduct details and calculation examples from the available sources.

EGRIFTA WR: reconstitute the 11.6 mg vial exclusively with the supplied 1.3 ml of bacteriostatic water to 8 mg/ml, swirl gently and do not shake. One vial contains seven daily doses. Conflicting community claims such as 1.45 ml or a blanket 28 days are not the current label.

Reconstitution & quantitiesOpen basics, units and sources
Explained in very simple termsBefore reading any number: this page reports what a product label, study or online community states. It does not say what any person should use.

Amount

mg or µg describe the mass of a substance. That is not the same as ml of fluid or U on a syringe. The number is only the amount stated by the identified source.

Interval

The interval only describes the time stated between two points. For example, once every 7 days does not mean daily and never justifies catching up or doubling.

Cycle

A cycle is a stated period that may include breaks. A community cycle proves neither effectiveness nor safety and does not prevent long-term risks.

Reconstitution

Reconstitution means mixing powder with a defined volume of fluid. This changes concentration, not the total amount in the vial. On U-100, 100 U equals exactly 1 ml of volume.

Not a guide to misuse

All community figures are shown only to place widely circulated online protocols in context. They are not instructions for self-use, injection, performance enhancement or any other misuse. Approved figures apply only to the exact named product, approved indication and medical supervision.

Research, risks & more detailsMechanism, adverse effects, storage, comparisons and common questions.

Mechanism: what is supported and what does not follow

Growth hormone-releasing factor analogue

Tesamorelin is classified as “Growth hormone-releasing factor analogue”. Stimulates endogenous growth-hormone release; approval is limited to a narrowly defined indication. This describes the investigated pathway but does not validate a community use, amount, route or combination.

01

GHRH analogue

This examines whether a growth hormone-releasing hormone analogue prompts the pituitary gland to release its own growth hormone, like a signal instructing the gland to release. Researchers measure growth hormone and IGF-1 levels in blood.

02

Growth hormone release

This studies how much growth hormone the pituitary gland releases into the blood after a stimulus, similar to measuring how much water flows out when a tap is briefly opened. Researchers typically draw blood samples at several time points to capture the size and timing of the release.

03

Growth-axis amplification

Researchers study how a substance amplifies the natural hormone chain from brain to pituitary to growth hormone, rather than supplying growth hormone directly. Hormone levels over time and muscle or fat mass are measured.

What communities discuss

These themes describe discussions and vendor claims. They do not prove benefit, safety, product identity or suitable use.

Bodybuilding forums

Here, muscle growth, strength gains, and recovery times are compared between different growth and repair peptides, often based on personal training logs. Vendor and user claims about muscle gains are anecdotal experience, not controlled study results.

Anti-aging forums

Combinations of growth-axis, mitochondrial, and skin peptides are compared here with the goal of influencing visible or felt signs of ageing, often documented personally over years. Anecdotes and vendor advertising about slowed ageing are not scientific proof.

Source and purity discussion

Discussion covers which vendors are seen as more trustworthy and how purity test results differ between batches. Such community assessments are based on limited samples and do not replace independent lab testing of each individual batch.

Adverse effects and safety risks

  • Interference with GH, IGF-1 or other hormone axes may cause oedema, joint or nerve symptoms, glucose intolerance, blood-pressure and hormonal changes; dependable human data are absent for many research substances.
  • Local reaction, infection, abscess and contamination are possible with any injection that is not professionally manufactured and administered.
  • A label or clear appearance does not exclude unknown purity, wrong identity, endotoxins or concentration errors.

Do not self-use / obtain clinical review

  • Active or previous malignancy, uncontrolled diabetes, intracranial disease, pregnancy/breastfeeding and hormone-sensitive disease require specialist assessment; approved products have specific contraindications.
  • Acute symptoms, allergic reaction, breathing difficulty, chest pain, neurological deficits or severe abdominal pain require immediate medical care.
  • Children and adolescents, pregnancy/breastfeeding, and people with relevant disease should not be part of unsupervised experiments.

Monitoring and laboratory markers

  • In medically justified use, IGF-1, fasting glucose/HbA1c, blood pressure, weight/oedema, thyroid and indication-specific hormones may be relevant; this is not a self-testing schedule.
  • Baseline, objective, measurement timing and stop criteria must be defined professionally in advance. Individual laboratory values cannot compensate for unknown product quality.

Evidence boundary

Established

Approval applies solely to the specific indication, not to general use.

Clinical evidence

The described biological role is well established, or extensive regulator-reviewed human data exist for clearly defined products and uses. This does not automatically transfer to other products or purposes.

Tesamorelin is approved only for a narrowly defined indication, unlike unregulated GHRH analogues such as CJC-1295.

Storage and stability

  • Store reconstituted EGRIFTA WR per the current label at 20–25 °C and discard after seven days.
  • WR and SV have different handling; do not transfer figures between formulations.

Troubleshooting and common errors

  • U-100 units measure volume, not drug amount: 100 U equals 1 mL. A wrong concentration makes every unit figure wrong.
  • Do not shake or dilute further to ‘fix’ cloudiness, particles or uncertain solubility; discard and obtain professional clarification.
  • Do not calculate a double or extra amount to compensate for missed use or an uncertain injection.
  • Without a COA, clear supplier, correct label and consistent vial information, identity is not confirmed.

Regulatory status and WADA

Approved for specific uses

Prescription active ingredient for defined indications in at least one jurisdiction; not offered here.

Combinations / stacks

  • Combinations change effects, adverse effects and laboratory values; evidence for one substance does not establish the safety of a stack.
  • Overlapping pathways may add up. Hormonal, glucose, blood-pressure, coagulation, immune and sedating effects are important potential interactions.
  • Non-standardised blends prevent separate dosing, cause attribution and dependable reconstitution.

Frequently asked questions

Is an amount shown here a recommendation?

No. This page separates approved product information, study protocols and community information. No number or calculator is an individual dosing recommendation.

Does the U-100 calculator prove correct use?

No. It only converts mass, volume and syringe scale. It cannot check identity, purity, sterility, stability, solvent or medical suitability.

Can this profile be combined with other substances?

Safety of a combination cannot be inferred from a single-substance profile. Overlapping pathways, medicines and undefined blends can increase risk.

Which source controls when information conflicts?

For approved medicines, the current prescribing information and treating professional control. For research substances, conflict shows that no dependable self-use standard exists.

Are community claims clinical evidence?

No. Anecdotes can generate questions but do not replace controlled studies, regulatory review, or identity and quality testing.

Back to all 64 profilesOpen scientific atlas profile